Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
吉利德公司定价4.25万美元的HIV药物每年可以制造出只有40美元，游说者敦促该公司大幅降价。
New research suggests that Gilead Sciences Inc.'s (NASDAQ:GILD) lenacapavir, sold as Sunlenca in the U.S. for HIV prevention, could cost patients just $40 annually.
新的研究表明，吉利德科学公司（纳斯达克：GILD）的Lenacapavir（在美国销售的Sunlenca，用于HIV预防）可能会让患者每年只需支付40美元。
Currently priced at $42,250 for the first year, campaigners urge the company to significantly reduce costs globally.
目前的价格为首年42250美元，倡导者敦促该公司全球大幅降低成本。
In December 2022, the FDA approved Lenacapavir in combination with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.
2022年12月，FDA批准Lenacapavir与其他抗逆转录病毒药物联合治疗重度耐多药HIV-1感染的成年人。
At the International AIDS Conference in Munich, experts presented a study estimating that a generic version of lenacapavir could be produced for $40 a year, assuming 10 million people used it annually.
在慕尼黑国际艾滋病会议上，专家发表了一项研究，估计一种Lenacapavir的仿制药每年可以以40美元的价格生产，假设每年1000万人使用它。
The Guardian...
《卫...
登录免费看全文
登录/注册